What made sesquiterpene lactones reach cancer clinical trials?
Publication type: Journal Article
Publication date: 2010-08-01
scimago Q1
wos Q1
SJR: 1.742
CiteScore: 16.0
Impact factor: 7.5
ISSN: 13596446, 18785832
PubMed ID:
20541036
Drug Discovery
Pharmacology
Abstract
Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
|
|
|
Molecules
23 publications, 4.35%
|
|
|
Natural Product Research
13 publications, 2.46%
|
|
|
International Journal of Molecular Sciences
10 publications, 1.89%
|
|
|
Biomedicine and Pharmacotherapy
10 publications, 1.89%
|
|
|
Journal of Ethnopharmacology
10 publications, 1.89%
|
|
|
Phytochemistry
9 publications, 1.7%
|
|
|
European Journal of Medicinal Chemistry
8 publications, 1.51%
|
|
|
Organic Letters
8 publications, 1.51%
|
|
|
Journal of Medicinal Chemistry
8 publications, 1.51%
|
|
|
International Immunopharmacology
7 publications, 1.32%
|
|
|
Fitoterapia
7 publications, 1.32%
|
|
|
Journal of Organic Chemistry
7 publications, 1.32%
|
|
|
Journal of Natural Products
7 publications, 1.32%
|
|
|
Organic and Biomolecular Chemistry
7 publications, 1.32%
|
|
|
European Journal of Pharmacology
6 publications, 1.13%
|
|
|
Bioorganic Chemistry
6 publications, 1.13%
|
|
|
Angewandte Chemie
6 publications, 1.13%
|
|
|
Angewandte Chemie - International Edition
6 publications, 1.13%
|
|
|
Planta Medica
6 publications, 1.13%
|
|
|
Natural Product Communications
5 publications, 0.95%
|
|
|
Scientific Reports
5 publications, 0.95%
|
|
|
Bioorganic and Medicinal Chemistry
5 publications, 0.95%
|
|
|
Biochemical Pharmacology
5 publications, 0.95%
|
|
|
Chemistry and Biodiversity
5 publications, 0.95%
|
|
|
Studies in Natural Products Chemistry
5 publications, 0.95%
|
|
|
Evidence-based Complementary and Alternative Medicine
5 publications, 0.95%
|
|
|
Oncology Reports
4 publications, 0.76%
|
|
|
Pharmaceuticals
4 publications, 0.76%
|
|
|
Biomedicines
4 publications, 0.76%
|
|
|
5
10
15
20
25
|
Publishers
|
20
40
60
80
100
120
140
160
|
|
|
Elsevier
154 publications, 29.11%
|
|
|
Wiley
62 publications, 11.72%
|
|
|
MDPI
59 publications, 11.15%
|
|
|
Springer Nature
52 publications, 9.83%
|
|
|
American Chemical Society (ACS)
42 publications, 7.94%
|
|
|
Taylor & Francis
29 publications, 5.48%
|
|
|
Royal Society of Chemistry (RSC)
28 publications, 5.29%
|
|
|
Hindawi Limited
13 publications, 2.46%
|
|
|
Bentham Science Publishers Ltd.
9 publications, 1.7%
|
|
|
Frontiers Media S.A.
9 publications, 1.7%
|
|
|
Spandidos Publications
8 publications, 1.51%
|
|
|
Georg Thieme Verlag KG
8 publications, 1.51%
|
|
|
SAGE
7 publications, 1.32%
|
|
|
Public Library of Science (PLoS)
4 publications, 0.76%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 0.57%
|
|
|
International Union of Crystallography (IUCr)
2 publications, 0.38%
|
|
|
American Society for Microbiology
2 publications, 0.38%
|
|
|
Cambridge University Press
2 publications, 0.38%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 0.38%
|
|
|
Beilstein-Institut
1 publication, 0.19%
|
|
|
American Society for Clinical Investigation
1 publication, 0.19%
|
|
|
National Research Council Canada
1 publication, 0.19%
|
|
|
Impact Journals
1 publication, 0.19%
|
|
|
Mary Ann Liebert
1 publication, 0.19%
|
|
|
PeerJ
1 publication, 0.19%
|
|
|
Pharmaceutical Society of Japan
1 publication, 0.19%
|
|
|
The Royal Society
1 publication, 0.19%
|
|
|
Pharmaceutical Society of Korea
1 publication, 0.19%
|
|
|
Korean Society of Food Science and Technology
1 publication, 0.19%
|
|
|
20
40
60
80
100
120
140
160
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
529
Total citations:
529
Citations from 2025:
31
(5.86%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Ghantous A. et al. What made sesquiterpene lactones reach cancer clinical trials? // Drug Discovery Today. 2010. Vol. 15. No. 15-16. pp. 668-678.
GOST all authors (up to 50)
Copy
Darwiche N., Gali-Muhtasib H., Vuorela H., Saliba N., Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? // Drug Discovery Today. 2010. Vol. 15. No. 15-16. pp. 668-678.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.drudis.2010.06.002
UR - https://doi.org/10.1016/j.drudis.2010.06.002
TI - What made sesquiterpene lactones reach cancer clinical trials?
T2 - Drug Discovery Today
AU - Darwiche, Nadine
AU - Gali-Muhtasib, Hala
AU - Vuorela, Heikki
AU - Saliba, Najat
AU - Darwiche, Nadine
PY - 2010
DA - 2010/08/01
PB - Elsevier
SP - 668-678
IS - 15-16
VL - 15
PMID - 20541036
SN - 1359-6446
SN - 1878-5832
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2010_Ghantous,
author = {Nadine Darwiche and Hala Gali-Muhtasib and Heikki Vuorela and Najat Saliba and Nadine Darwiche},
title = {What made sesquiterpene lactones reach cancer clinical trials?},
journal = {Drug Discovery Today},
year = {2010},
volume = {15},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/j.drudis.2010.06.002},
number = {15-16},
pages = {668--678},
doi = {10.1016/j.drudis.2010.06.002}
}
Cite this
MLA
Copy
Ghantous, Akram, et al. “What made sesquiterpene lactones reach cancer clinical trials?.” Drug Discovery Today, vol. 15, no. 15-16, Aug. 2010, pp. 668-678. https://doi.org/10.1016/j.drudis.2010.06.002.